Graceptor®

Pre-clinicalCompleted

0 views this week 0 watching💤 Quiet

Interest: 26/100

Hype Score

Development Stage

Pre-clinical

Phase 1

Phase 2

Phase 3

Approved

Indication / Disease

the Maintenance Phase After Kidney Transplantation

Conditions

the Maintenance Phase After Kidney Transplantation

Trial Timeline

Nov 15, 2013 → Mar 31, 2016

NCT ID

NCT02160054

About Graceptor®

Graceptor® is a pre-clinical stage product being developed by Astellas Pharma for the Maintenance Phase After Kidney Transplantation. The current trial status is completed. This product is registered under clinical trial identifier NCT02160054. Target conditions include the Maintenance Phase After Kidney Transplantation.

What happened to similar drugs?

7 of 20 similar drugs in the Maintenance Phase After Kidney Transplantation were approved

Approved (7) Terminated (1) Active (12)

✅Zolpidem MR + EstazolamAstellas PharmaApproved

🔄zolpidem MR + nitrazepam + placeboAstellas PharmaPhase 3

🔄FK199B + ZolpidemAstellas PharmaPhase 3

✅Zolpidem MR + Zolpidem IRAstellas PharmaApproved

🔄Zolpidem MR + ZolpidemAstellas PharmaPhase 3

🔄Lemborexant + PlaceboEisaiPhase 3

✅Eszopiclone + Fluoxetine + PlaceboSumitomo PharmaApproved

Hype Score Breakdown

Clinical

Activity

Company

Novelty

Community

Clinical Trials (1)

NCT ID	Phase	Status	Start	Completion	Indication
NCT02160054	Pre-clinical	Completed	Nov 15, 2013	Mar 31, 2016	the Maintenance Phase After Kidney Transplantation

Competing Products

20 competing products in the Maintenance Phase After Kidney Transplantation

See all competitors

Product	Company	Stage	Hype Score
LY2422347 + placebo	Eli Lilly	Phase 2	35
LY2624803 - Solution + LY2624803 - Capsule + Placebo - Solution + Placebo - Capsule	Eli Lilly	Phase 1	29
Zolpidem MR + Estazolam	Astellas Pharma	Approved	43
zolpidem MR + nitrazepam + placebo	Astellas Pharma	Phase 3	40
FK199B + Zolpidem	Astellas Pharma	Phase 3	40
ASP7991	Astellas Pharma	Phase 1	29
Zolpidem MR + Zolpidem IR	Astellas Pharma	Approved	43
Zolpidem MR + Zolpidem	Astellas Pharma	Phase 3	40
Lemborexant	Eisai	Phase 2	35
Lemborexant + Placebo	Eisai	Phase 3	40
Lemborexant	Eisai	Pre-clinical	26
Eszopiclone + Fluoxetine + Placebo	Sumitomo Pharma	Approved	43
Org 50081 + Org 50081 + Placebo + zopiclone	Merck	Phase 1	29
esmirtazapine	Merck	Phase 3	32
Esmirtazapine	Merck	Phase 3	40
Suvorexant + Placebo	Merck	Phase 3	40
Esmirtazapine + Placebo	Merck	Phase 3	40
Enteric-coated Mycophenolate sodium (EC-MPS) + Mycophenolate mofetil	Novartis	Approved	43
Cyclosporine - cyclosporine microemulsion	Novartis	Approved	43
Enteric-coated Mycophenolate sodium (EC-MPS)	Novartis	Approved	43